| 计悠扬,王一涵,李畅畅,韩颖.依达拉奉联合阿替普酶对老年急性脑梗死患者再灌注的影响[J].中国临床保健杂志,2019,22(2):233-236. |
| 依达拉奉联合阿替普酶对老年急性脑梗死患者再灌注的影响 |
| Edaravone combined alteplase on the influence of brain reperfusion for elderly patients with acute cerebral infarction |
| 投稿时间：2017-11-23 |
| DOI：10.3969/J.issn.1672-6790.2019.02.023 |
| 中文关键词: 脑梗死 再灌注 自由基清除剂 组织型纤溶酶原激活物 老年人 |
| 英文关键词: Brain Infarction Reperfusion Free radical scavengers Tissue plasminogen activator Aged 〖FL |
| 基金项目: |
|
| 摘要点击次数: 5764 |
| 全文下载次数: 4552 |
| 中文摘要: |
| 目的 探讨依达拉奉联合阿替普酶对老年急性脑梗死(ACI)患者再灌注的影响。 方法 选取老年ACI患者156例,采用随机数字表法将患者分为研究组(n=79)与对照组(n=77)。对照组采用阿替普酶治疗,研究组采用依达拉奉联合阿替普酶治疗,比较两组再灌注损伤、临床疗效、生化指标与药物安全性的差异。 结果 研究组治疗总有效率(92.41%)明显高于对照组(68.83%),(χ2=13.951,P<0.001)。研究组再灌注损伤发生率(2.53%)明显低于对照组(14.29%),两组差异有统计学意义(χ2=7.052,P=0.005)。治疗前,两组神经元特异性烯醇酶(NSE)、丙二醛(MDA) 、超氧化物歧化酶(SOD)、超敏C反应蛋白(hs-CRP)、内皮素(ET) 水平 [(26.31±4.98)μg/L比(26.28±5.02)μg/L,(9.65±1.46)nmol/mL比(9.71±1.52)nmol/mL,(67.95±14.28)u/mL比(67.85±15.03)u/mL,(11.26±1.56)μmol/L比(11.31±1.63)μmol/L,(77.69±9.01)ng/L比(77.71±8.69)ng/L] 比较,差异无统计学意义(t=0.037,0.251,0.043,0.196,0.014;P=0.971,0.802,0.966,0.845,0.989)。治疗后,两组SOD水平[(109.68±20.17)nmol/mL、(90.25±14.36)nmol/mL]明显高于治疗前,NSE、MDA、hs-CRP、ET水平明显低于治疗前(P均<0.001),其中研究组SOD水平明显高于对照组,NSE、MDA、hs-CRP、ET水平明显低于对照组(P均<0.001)。出院后持续随访3个月,研究组死亡率(0.00%)明显低于对照组(15.58%),χ2=13.338,P<0.001。 结论 依达拉奉联合阿替普酶有助于明显降低老年ACI患者再灌注损伤,改善生化指标与预后状况,且药物安全性较高。 |
| 英文摘要: |
| Objective To study edaravone combined alteplase on the influence of brain reperfusion for elderly patients with acute cerebral infarction (ACI). Methods 156 cases of elderly patients with ACI were selected,the patients were divided into research group (n=79) and control group (n=77) by using the random number table method.The control group was given alteplase treatment,the research group was given edaravone combined with alteplase treatment.The differences of reperfusion injury,clinical effect,biochemical indexes and drug safety between the two groups were compared. Results The total effective rate in the research group was 92.41%,which was significantly higher than that (68.83%) of the control group (χ2=13.951,P<0.001).Reperfusion injury rate in the research group was 2.53%,significantly lower than that (14.29%) of the control group (χ2=7.052,P=0.005).Before the treatment,serum neuron specific enolase (NSE),malondialdehyde (MDA),superoxide dismutase (SOD),hypersensitive c-reactive protein (hs-CRP),endothelin (ET) levels were compared between the two groups with no statistically significant differences.After the treatment,SOD level was significantly higher than that of pre-therapy,the levels of NSE,MDA,hs-CRP,ET were lower than those of pre-therapy in two groups.SOD of the research group was obviously higher,and the levels of NSE,MDA,hs-CRP and ET were significantly lower than those of the control group.With continuously out-hospital following-up for 3 months,the mortality of the research group (0.00%) was significantly lower than that of the control group (15.58%,χ2=13.338,P<0.001). Conclusion Edaravone combined with alteplase can decrease reperfusion injury for elderly patients with ACI and improve biochemical indicators and prognosis with good safety. |
|
查看全文
|
| 关闭 |
|
|
|